Meta-Analysis of Chemotherapy in Nasopharynx Carcinoma (MAC-NPC): an update on 26 trials and 7080 patients

[1]  W. Feng,et al.  Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN-1st): a multicentre, randomised, double-blind, phase 3 trial. , 2021, The Lancet. Oncology.

[2]  K. Harrington,et al.  Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial. , 2021, The Lancet. Oncology.

[3]  Jun Ma,et al.  Chemotherapy in Combination With Radiotherapy for Definitive-Intent Treatment of Stage II-IVA Nasopharyngeal Carcinoma: CSCO and ASCO Guideline. , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  H. Sze,et al.  NPC‐0501 trial on the value of changing chemoradiotherapy sequence, replacing 5‐fluorouracil with capecitabine, and altering fractionation for patients with advanced nasopharyngeal carcinoma , 2020, Cancer.

[5]  Bin Zhang,et al.  Association of Chemoradiotherapy Regimens and Survival Among Patients With Nasopharyngeal Carcinoma , 2019, JAMA network open.

[6]  C. Qian,et al.  Induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: long-term results of a phase III multicentre randomised controlled trial. , 2019, European journal of cancer.

[7]  Ying Sun,et al.  Concurrent chemoradiotherapy with/without induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma: Long‐term results of phase 3 randomized controlled trial , 2019, International journal of cancer.

[8]  Yingqin Li,et al.  Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal Carcinoma. , 2019, The New England journal of medicine.

[9]  Min Zhou,et al.  Combination treatment with cetuximab in advanced nasopharyngeal carcinoma patients: a meta-analysis , 2019, OncoTargets and therapy.

[10]  Ying Sun,et al.  Ten-year outcomes of survival and toxicity for a phase III randomised trial of concurrent chemoradiotherapy versus radiotherapy alone in stage II nasopharyngeal carcinoma. , 2019, European journal of cancer.

[11]  Hung-Ming Wang,et al.  Final results of a randomized phase III trial of induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in patients with stage IVA and IVB nasopharyngeal carcinoma-Taiwan Cooperative Oncology Group (TCOG) 1303 Study , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[12]  J. Pignon,et al.  Impact of missing individual patient data on 18 meta-analyses of randomised trials in oncology: Gustave Roussy experience , 2018, BMJ Open.

[13]  A. King,et al.  Analysis of Plasma Epstein-Barr Virus DNA in Nasopharyngeal Cancer After Chemoradiation to Identify High-Risk Patients for Adjuvant Chemotherapy: A Randomized Controlled Trial. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  Y. Soon,et al.  Induction chemotherapy for locally advanced nasopharyngeal carcinoma treated with concurrent chemoradiation: A systematic review and meta-analysis. , 2018, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[15]  J. Bourhis,et al.  A randomized trial of induction docetaxel–cisplatin–5FU followed by concomitant cisplatin-RT versus concomitant cisplatin-RT in nasopharyngeal carcinoma (GORTEC 2006-02) , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[16]  B. O'Sullivan,et al.  A multicenter, phase 3, randomized trial of concurrent chemoradiotherapy plus adjuvant chemotherapy versus radiotherapy alone in patients with regionally advanced nasopharyngeal carcinoma: 10‐year outcomes for efficacy and toxicity , 2017, Cancer.

[17]  M. Parmar,et al.  Role of radiotherapy fractionation in head and neck cancers (MARCH): an updated meta-analysis. , 2017, The Lancet. Oncology.

[18]  Ying Sun,et al.  Adjuvant chemotherapy in patients with locoregionally advanced nasopharyngeal carcinoma: Long-term results of a phase 3 multicentre randomised controlled trial. , 2017, European journal of cancer.

[19]  George Fountzilas,et al.  What Is the Best Treatment of Locally Advanced Nasopharyngeal Carcinoma? An Individual Patient Data Network Meta-Analysis. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  S. Liang,et al.  Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicentre, randomised controlled trial. , 2016, The Lancet. Oncology.

[21]  B. Jeremic,et al.  Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 107 randomized trials and 19805 patients, on behalf of MACH-NC group. , 2016, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[22]  C. Qian,et al.  Ten-year outcomes of a randomised trial for locoregionally advanced nasopharyngeal carcinoma: A single-institution experience from an endemic area. , 2015, European journal of cancer.

[23]  I. Chitapanarux,et al.  OP0005 Neoadjuvant chemotherapy plus chemoradiation (NACT-CCRT) versus chemoradiation plus adjuvant chemotherapy (CCRT-ACT) for locally advanced nasopharyngeal cancer: 3-Year results from a randomised trial , 2015 .

[24]  Jun Ma,et al.  Chemotherapy and radiotherapy in nasopharyngeal carcinoma: an update of the MAC-NPC meta-analysis. , 2015, The Lancet. Oncology.

[25]  K. Soo,et al.  Concurrent chemo-radiation with or without induction gemcitabine, Carboplatin, and Paclitaxel: a randomized, phase 2/3 trial in locally advanced nasopharyngeal carcinoma. , 2015, International journal of radiation oncology, biology, physics.

[26]  W. Liang,et al.  Long-term follow-up of a phase III study comparing radiotherapy with or without weekly oxaliplatin for locoregionally advanced nasopharyngeal carcinoma. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[27]  Ying Sun,et al.  Progress report of a randomized trial comparing long‐term survival and late toxicity of concurrent chemoradiotherapy with adjuvant chemotherapy versus radiotherapy alone in patients with stage III to IVB nasopharyngeal carcinoma from endemic regions of China , 2013, Cancer.

[28]  R. Sun,et al.  A randomized trial of induction chemotherapy plus concurrent chemoradiotherapy versus induction chemotherapy plus radiotherapy for locoregionally advanced nasopharyngeal carcinoma. , 2012, Oral oncology.

[29]  T. Ciuleanu,et al.  Induction chemotherapy followed by concomitant radiotherapy and weekly cisplatin versus the same concomitant chemoradiotherapy in patients with nasopharyngeal carcinoma: a randomized phase II study conducted by the Hellenic Cooperative Oncology Group (HeCOG) with biomarker evaluation. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[30]  R. Sun,et al.  Concurrent chemoradiotherapy vs radiotherapy alone in stage II nasopharyngeal carcinoma: phase III randomized trial. , 2011, Journal of the National Cancer Institute.

[31]  J F Tierney,et al.  A critical review of methods for the assessment of patient-level interactions in individual participant data meta-analysis of randomized trials, and guidance for practitioners. , 2011, Journal of clinical epidemiology.

[32]  B. O'Sullivan,et al.  Randomized trial of radiotherapy plus concurrent-adjuvant chemotherapy vs radiotherapy alone for regionally advanced nasopharyngeal carcinoma. , 2010, Journal of the National Cancer Institute.

[33]  A. King,et al.  Randomized phase II trial of concurrent cisplatin-radiotherapy with or without neoadjuvant docetaxel and cisplatin in advanced nasopharyngeal carcinoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  J. Sham,et al.  Long-term results of concurrent and adjuvant chemotherapy for advanced nasopharyngeal carcinoma , 2008 .

[35]  D. Machin,et al.  Randomized trial of radiotherapy versus concurrent chemoradiotherapy followed by adjuvant chemotherapy in patients with American Joint Committee on Cancer/International Union against cancer stage III and IV nasopharyngeal cancer of the endemic variety. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  T. Mok,et al.  Overall survival after concurrent cisplatin-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma. , 2005, Journal of the National Cancer Institute.

[37]  J. Sham,et al.  Concurrent and adjuvant chemotherapy for nasopharyngeal carcinoma: a factorial study. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  S. Thompson,et al.  Quantifying heterogeneity in a meta‐analysis , 2002, Statistics in medicine.

[39]  S. Fukuda,et al.  A prospective, randomized trial comparing neoadjuvant chemotherapy with radiotherapy alone in patients with advanced nasopharyngeal carcinoma , 2002, Cancer.

[40]  Yue-Cune Chang,et al.  A phase III study of adjuvant chemotherapy in advanced nasopharyngeal carcinoma patients. , 2002, International journal of radiation oncology, biology, physics.

[41]  Robert Gray,et al.  A Proportional Hazards Model for the Subdistribution of a Competing Risk , 1999 .

[42]  M. Leblanc,et al.  Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  M Schemper,et al.  A note on quantifying follow-up in studies of failure time. , 1996, Controlled clinical trials.

[44]  L. Stewart,et al.  Practical methodology of meta-analyses (overviews) using updated individual patient data. Cochrane Working Group. , 1995, Statistics in medicine.

[45]  S. Leung,et al.  A prospective randomized study of chemotherapy adjunctive to definitive radiotherapy in advanced nasopharyngeal carcinoma. , 1995, International journal of radiation oncology, biology, physics.

[46]  O. Brodin,et al.  Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials , 1995 .

[47]  M. Parmar,et al.  Meta-analysis of the literature or of individual patient data: is there a difference? , 1993, The Lancet.

[48]  R. Peto,et al.  Beta blockade during and after myocardial infarction: an overview of the randomized trials. , 1985, Progress in cardiovascular diseases.

[49]  Jun Ma,et al.  Nasopharyngeal carcinoma , 2019, The Lancet.

[50]  B. O'Sullivan,et al.  A randomized trial on addition of concurrent-adjuvant chemotherapy and/or accelerated fractionation for locally-advanced nasopharyngeal carcinoma. , 2011, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[51]  J. Sham,et al.  Patterns of failure after induction chemotherapy and radiotherapy for locoregionally advanced nasopharyngeal carcinoma: the Queen Mary Hospital experience. , 2001, International journal of radiation oncology, biology, physics.